- Home
- WTW vs IQV Comparison
WTW vs IQV Comparison
Compare WTW & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTW
- IQV
- Stock Information
- Founded
- WTW 1828
- IQV 1982
- Country
- WTW United Kingdom
- IQV United States
- Employees
- WTW N/A
- IQV N/A
- Industry
- WTW Specialty Insurers
- IQV Biotechnology: Commercial Physical & Biological Resarch
- Sector
- WTW Finance
- IQV Health Care
- Exchange
- WTW Nasdaq
- IQV Nasdaq
- Market Cap
- WTW 31.9B
- IQV 38.1B
- IPO Year
- WTW N/A
- IQV 2013
- Fundamental
- Price
- WTW $312.65
- IQV $192.62
- Analyst Decision
- WTW Buy
- IQV Buy
- Analyst Count
- WTW 15
- IQV 16
- Target Price
- WTW $313.93
- IQV $259.40
- AVG Volume (30 Days)
- WTW 678.3K
- IQV 1.9M
- Earning Date
- WTW 10-31-2024
- IQV 10-31-2024
- Dividend Yield
- WTW 1.13%
- IQV N/A
- EPS Growth
- WTW N/A
- IQV 27.98
- EPS
- WTW N/A
- IQV 7.62
- Revenue
- WTW $9,809,000,000.00
- IQV $15,315,000,000.00
- Revenue This Year
- WTW $5.66
- IQV $3.68
- Revenue Next Year
- WTW $1.66
- IQV $4.89
- P/E Ratio
- WTW N/A
- IQV $25.29
- Revenue Growth
- WTW 5.58
- IQV 3.10
- 52 Week Low
- WTW $234.01
- IQV $189.63
- 52 Week High
- WTW $320.77
- IQV $261.73
- Technical
- Relative Strength Index (RSI)
- WTW 64.20
- IQV 26.80
- Support Level
- WTW $314.54
- IQV $216.74
- Resistance Level
- WTW $318.85
- IQV $225.91
- Average True Range (ATR)
- WTW 5.43
- IQV 7.63
- MACD
- WTW 0.92
- IQV -1.28
- Stochastic Oscillator
- WTW 72.57
- IQV 8.24
About WTW Willis Towers Watson Public Limited Company
In January 2016, Towers Watson and Willis Group merged to form Willis Towers Watson, a global advisory, insurance brokerage, and solutions company. The company operates in two business segments: health, wealth, and career (its consulting operations) and risk and brokering (its brokerage operations). It has about 48,000 employees.
About IQV IQVIA Holdings Inc.
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.